Signaturefd LLC Boosts Stake in Revvity, Inc. (NYSE:RVTY)

Signaturefd LLC grew its position in Revvity, Inc. (NYSE:RVTY) by 6.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,668 shares of the company’s stock after buying an additional 106 shares during the quarter. Signaturefd LLC’s holdings in Revvity were worth $186,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC grew its stake in shares of Revvity by 1.7% in the third quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company’s stock valued at $809,332,000 after buying an additional 108,401 shares in the last quarter. State Street Corp grew its stake in shares of Revvity by 0.3% in the third quarter. State Street Corp now owns 5,180,169 shares of the company’s stock valued at $661,767,000 after buying an additional 17,832 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Revvity by 0.9% in the third quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company’s stock valued at $364,569,000 after buying an additional 25,078 shares in the last quarter. EdgePoint Investment Group Inc. grew its stake in shares of Revvity by 34.6% in the third quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company’s stock valued at $343,108,000 after buying an additional 690,534 shares in the last quarter. Finally, RGM Capital LLC grew its stake in shares of Revvity by 3.2% in the third quarter. RGM Capital LLC now owns 980,858 shares of the company’s stock valued at $125,305,000 after buying an additional 30,000 shares in the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Trading Up 0.2 %

NYSE:RVTY opened at $107.18 on Friday. The stock has a 50-day simple moving average of $116.44 and a 200-day simple moving average of $117.54. The stock has a market cap of $12.88 billion, a P/E ratio of 48.50, a P/E/G ratio of 3.82 and a beta of 1.06. Revvity, Inc. has a 1 year low of $97.32 and a 1 year high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60.

Revvity (NYSE:RVTY) last posted its earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the prior year, the company posted $1.25 earnings per share. As a group, analysts anticipate that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.26%. The ex-dividend date is Thursday, April 17th. Revvity’s payout ratio is currently 12.67%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on RVTY. Barclays lifted their price objective on Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Sanford C. Bernstein cut Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price for the company. in a research note on Friday, January 10th. Bank of America raised Revvity from a “neutral” rating to a “buy” rating and set a $138.00 target price for the company in a research note on Friday, December 13th. KeyCorp boosted their target price on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, Raymond James reissued an “outperform” rating and set a $145.00 target price (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $136.25.

Insider Activity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now directly owns 33,400 shares of the company’s stock, valued at $4,232,782. This represents a 31.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tajinder S. Vohra sold 5,492 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now directly owns 19,652 shares of the company’s stock, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.60% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.